Hint mode is switched on Switch off
For swift navigation between sections

Zenas Biopharma Bonds, 2.5% 1apr2032, USD (Conv.) (FIGI BBG021B95MK7)

Download
Copy issue information to clipboard
Copy issue information to clipboard
Copy to clipboard
Data copied to the clipboard

PDF download

Choose all Reset all
Download Cancel

Domestic bonds, Convertible, Trace-eligible, Senior Unsecured

Status
Outstanding
Amount
200,000,000 USD
Placement
***
Redemption (put/call option)
*** (-)
ACI
Country of risk
USA
Current coupon
***%
Price
Yield / Duration
Calculate in two clicks! yield, duration and other parameters
Calculate in two clicks! yield, duration and other parameters
Calculator What is a calculator?
  • Placement amount
    200,000,000 USD
  • Outstanding amount
    200,000,000 USD
  • USD equivalent
    200,000,000 USD
  • Face value
    1,000 USD
  • FIGI
    BBG021B95MK7
  • Ticker
    ZBIO 2.5 04/01/32

Try in 7-days Trial access

Free for company representative

  • Get full online access to the database
  • Use our powerful bond screener
  • Track bond prices from 400+ sources
  • Smart Portfolio Monitoring
  • Evaluate advanced analytical tools
Sign up

Why Cbonds?

  • 24 Years of Market Leadership
  • Trusted by clients across 90 countries for decades of reliable service
  • Used by Financial Professionals & Fintech central banks, asset managers, fintech innovators
  • Convenient platform for private investors for informed investment decisions

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Explore the most comprehensive database

1 000 000

bonds

80 234

stocks

167 970

ETF & Funds

70 000

indices

Track your portfolio in the most efficient way

  • Bond Search
  • Watchlist
  • Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Files

Final Terms

Authorization required
It is only possible to download bond prospectuses for paid Premium subscription access

Trading chart

Stock exchange selection
Stock exchange selection
More about Cbonds Estimation
No more than two exchanges can be selected for comparison at the same time
Data display in a chart | table
Data display in a chart | table
Work with the chart: switching the price, period, issue comparison
Work with the chart: switching the price, period, issue comparison
Customize fields in the table
Found:
Show all fields
from
to
ADD-IN
Cbonds add-in API
bond data api
Authorization required
You need to request access
* Data is not available within the selected subscription

Issue information

Profile
Zenas Biopharma, Inc. operates as a biopharmaceutical company. The Company focuses on development and commercialization of immunology-based therapies for multiple autoimmune diseases. Zenas Biopharma serves patients and healthcare professionals worldwide.
Research report by Cbonds-PRAAMS Save
Authorization required
Report download is available only paid Premium subscription access
Volume
  • Placement amount
    200,000,000 USD
  • Outstanding amount
    200,000,000 USD
  • Outstanding face value amount
    200,000,000 USD
Face value
  • Minimum Settlement Amount
    1,000 USD
  • Face value
    1,000 USD
  • Outstanding face value
    *** USD
  • Increment
    *** USD

Get access to the largest bond database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest bond database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Cash flow parameters

  • Reference rate
    ***
  • Coupon Rate
    ***
  • Day count convention
    ***
  • Interest Accrual Date
    ***
  • Coupon frequency
    *** time(s) per year
  • Payment currency
    ***
  • Maturity date
    ***

Cash flow

Export to Excel

Early redemption terms

***

Explore the most comprehensive database

1 000 000

bonds

80 234

stocks

167 970

ETF & Funds

70 000

indices

Track your portfolio in the most efficient way

  • Bond Search
  • Watchlist
  • Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Placement

  • Placement method
    Open subscription
  • Placement type
    Public
  • Placement
    ***
  • Initial issue price (yield)
  • Geographic breakdown
    ***
  • Investor breakdown
    ***
  • Use of proceeds
    General Corporate Purposes
    Working Capital
    Project Financing
  • Use of proceeds description
    The Issuer intends to use the net proceeds from the Convertible Notes Offering, together with the net proceeds from the concurrent Common Stock Offering, to support the planned U.S. commercial launch of obexelimab for the treatment of IgG4-RD, if approved, and to advance our development pipeline, including funding our ongoing and planned orelabrutinib Phase 3 clinical trials for progressive multiple sclerosis and ZB021 Phase 1 and Phase 2 clinical development, as well as for working capital and other general corporate purposes
Participants
  • Bookrunner
    ***, ***, ***, ***
  • Depository
    ***

Conversion and exchange

  • Initial premium
    ***%
  • Convertible until
    ***
  • Conversion terms
    ***

Similar issues

News

11/05/2026 Zenas Biopharma: Results Of Operations And Financial Condition, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Submission Of Matters To A Vote Of Security Holders, Financial Statements And Exhibits
26/03/2026 Zenas Biopharma: Entry Into A Material Definitive Agreement, Creation Of A Direct Financial Obligation Or An Offbalance Sheet Arrangement, Other Events, Financial Statements And Exhibits
05/01/2026 Zenas Biopharma: Results Of Operations And Financial Condition, Regulation Fd Disclosure, Other Events, Financial Statements And Exhibits
22/12/2025 Zenas BioPharma, Inc. (NASDAQ: ZBIO) Maintains "Buy" Rating and Grants Stock Options
10/12/2025 Zenas Biopharma: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Financial Statements And Exhibits
All organization news

IFRS/US GAAP reports

2025
I q eng
2024
III q eng
IV q eng
Show all Hide
Authorization required
You need to request access

Identifiers

  • ISIN
    ***
  • Cbonds ID
    2116089
  • CUSIP
    ***
  • CUSIP 144A
    ***
  • FIGI
    BBG021B95MK7
  • Ticker
    ZBIO 2.5 04/01/32
  • Type of security by CBR
    ***

Bond classification

  • Senior Unsecured
  • Coupon bonds
  • Convertible
  • Trace-eligible
  • Amortization
  • Callable
  • CDO
  • Dual currency bonds
  • Variable rate
  • For qualified investors (CIS region)
  • Foreign bonds
  • Green bonds
  • Guaranteed
  • Inflation-linked principal
  • Supranational bond issues
  • Inflation-linked coupon
  • Mortgage bonds
  • Non-complex financial instruments (MiFID)
  • Perpetual
  • Payment-in-kind
  • Non-Marketable Securities
  • Redemption Linked
  • Restructuring
  • Retail bonds
  • Covered
  • Securitization
  • Structured product
  • Commercial Bonds
  • Subordinated
  • Sukuk
Show more Hide

Restructuring

***

Registration is required to get access.